Phaseline

Companies › Tiohundra

Tiohundra: clinical trials, targets and expected readouts

2 active drug programs in 40 registered trials: 20 Phase 4, 12 Phase 3, 6 Phase 2, 2 Phase 1; Cardiovascular, Genitourinary, Infectious disease, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Hydrocortisone
Glucocorticoid receptor agonist
NR3C1Phase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Pituitary Adenoma; Adrenal Insufficiency; Shock …Jan 2027
Vasopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock …Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06934798VasopressinPhase 4Vasoplegic Syndrome of Cardiac SurgeryCardiovascularJul 2025
NCT06547892VasopressinPhase 2Critical IllnessOtherOct 2025
NCT04591990HydrocortisonePhase 3Postresuscitation SyndromeMetabolic and endocrineDec 2025
NCT05668455HydrocortisonePhase 3Ocular InflammationImmunologyDec 2025
NCT06679816HydrocortisonePhase 4Pituitary AdenomaOncologyDec 2025
NCT05193396HydrocortisonePhase 4Adrenal InsufficiencyGenitourinaryJan 2026
NCT05816226HydrocortisonePhase 3TMJ PainOtherJan 2026
NCT04404400HydrocortisonePhase 3Critical Illness Related Corticosteroids InsufficiencyMetabolic and endocrineFeb 2026
NCT05568160VasopressinPhase 3Scheduled Cardiac Surgery With Extracorporeal CirculationCardiovascularMar 2026
NCT07248761HydrocortisonePhase 4ShockInfectious diseaseJun 2026
NCT06982183HydrocortisonePhase 4Fear of SpidersPsychiatrySep 2026
NCT07102615VasopressinPhase 4Retained Products of ConceptionOtherDec 2026
NCT02118467VasopressinPhase 4ShockCardiovascularDec 2026
NCT07124650HydrocortisonePhase 4Postoperative Sore Throat, Cough, HoarsenessMetabolic and endocrineDec 2026
NCT03446456VasopressinPhase 1Acute PainMetabolic and endocrineDec 2026
NCT03760835HydrocortisonePhase 4Congenital Adrenal HyperplasiaGenitourinaryDec 2026
NCT03401398HydrocortisonePhase 3Septic ShockInfectious diseaseDec 2026
NCT05160506HydrocortisonePhase 2PancreatitisGastroenterologyJan 2027
NCT05139849VasopressinPhase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical TrialCardiovascularJan 2027
NCT05139849HydrocortisonePhase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical TrialCardiovascularJan 2027
NCT05958342VasopressinPhase 2TraumaMetabolic and endocrineMar 2027
NCT06895473HydrocortisonePhase 2Hematopoietic and Lymphatic System NeoplasmOncologyApr 2027
NCT06709573VasopressinPhase 4SepsisInfectious diseaseMay 2027
NCT06709573VasopressinPhase 4SepsisInfectious diseaseMay 2027
NCT06344442VasopressinPhase 3Acute Kidney Injury Post Liver TransplantationGenitourinaryMay 2027
NCT00859781HydrocortisonePhase 2Prostate CancerOncologyJun 2027
NCT04082533HydrocortisonePhase 4PainImmunologyJul 2027
NCT06464510VasopressinPhase 3Septic ShockMetabolic and endocrineAug 2027
NCT07262957HydrocortisonePhase 4Pancreas Head CancerOncologySep 2027
NCT05836610HydrocortisonePhase 4Hypoxic-Ischemic EncephalopathyCardiovascularSep 2027
NCT07052084VasopressinPhase 3Septic ShockOtherFeb 2028
NCT05738148VasopressinPhase 1Cardiac Arrest NeonatalCardiovascularFeb 2028
NCT05435781HydrocortisonePhase 4Adrenal InsufficiencyGenitourinaryMar 2028
NCT07763210HydrocortisonePhase 2Non-hodgkin LymphomaOncologyMar 2028
NCT07037043HydrocortisonePhase 3Inflammation in Cardiac SurgeryCardiovascularMay 2028
NCT07383103HydrocortisonePhase 4Septic ShockOtherDec 2028
NCT06881927HydrocortisonePhase 4Sepsis and Septic ShockInfectious diseaseAug 2029
NCT02775227HydrocortisonePhase 4Pancreatic FistulaOncologyDec 2029
NCT06892197HydrocortisonePhase 4Community Acquired Pneumonia (CAP)RespiratoryAug 2030
NCT06892210HydrocortisonePhase 4Chronic Obstructive Pulmonary Disease (COPD)RespiratoryAug 2030

Targets

AVPR2 (1) AVPR1A (1) AVPR1B (1) NR3C1 (1)

Companies with the same targets

Corcept Therapeutics PharmaIN Otsuka Newleos Therapeutics Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Alimera Sciences Laboratorios Sophia S.A de C.V. Optinose US

Companies built like this

Insud Pharma Brainfarma Industria Química e Farmacêutica S/A Optinose US Laboratorio Elea Phoenix Biocodex

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.